Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

(2017) Mark A Boyd et al.   Lancet HIV

Long-term body composition changes in antiretroviral-treated HIV-infected individuals

(2016) Philip M. Grant et al.   AIDS

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

(2016) Grace A. McComsey et al.   CLINICAL INFECTIOUS DISEASES

A longitudinal study of systemic inflammation and recovery of lean body mass among malnourished HIV-infected adults starting antiretroviral therapy in Tanzania and Zambia

(2016) G PrayGod et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

From Wasting to Obesity: The Contribution of Nutritional Status to Immune Activation in HIV Infection

(2016) John R. Koethe et al.   JOURNAL OF INFECTIOUS DISEASES

From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century

(2015) Matthias Blüher et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

(2015) Jose I Bernardino et al.   Lancet HIV

Adipokines, hormones related to body composition, and insulin resistance in HIV fat redistribution syndrome

(2014) Paula Freitas et al.   BMC INFECTIOUS DISEASES

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health

(2014) Roger J. Bedimo et al.   PLoS One

Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy–Naive HIV-1–Infected Individuals

(2013) Todd T. Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

(2012) Jacques Reynes et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF–Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202

(2012) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

(2010) Jeffrey L Lennox et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels

(2008) Jason S Reingold et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES